Mouse tumour models to guide drug development and identify resistance mechanisms

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 103-111

  Das Thakur, Meghna ^a   Pryer, Nancy K ^a   Singh, Mallika ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

cancer; GEMM; mouse model; PDX; resistance; targeted therapy; xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; ERLOTINIB; GEFITINIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAF PROTEIN; RAF PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ADVANCED CANCER; B CELL LYMPHOMA; BREAST TUMOR; CANCER GROWTH; CANCER RESISTANCE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; GENETIC ENGINEERING; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RNA TRANSLATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT;

CANCER; GEMM; MOUSE MODEL; PDX; RESISTANCE; TARGETED THERAPY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890291629     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4285     Document Type: Review

References (66)

1. PhRMA. More than 800 medicines and vaccines in testing offer hope in the fight against cancer; 2009: http://www.healthinfoispower.files.wordpress.com/ 2009/04/phrmacancer.pdf
2. Reichert JM, Wenger JB,. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13: 30-37.
3. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Boehm JS, Hahn WC,. Towards systematic functional characterization of cancer genomes. Nat Rev Genet 2011; 12: 487-498.
5. Tuveson DA, Jacks T,. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002; 12: 105-110.
6. Singh M, Ferrara N,. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2012; 30: 648-657.
7. Kerbel RS,. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003; 2: S134-139.
8. Voskoglou-Nomikos T, Pater JL, Seymour L,. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9: 4227-4239.
9. Siolas D, Hannon GJ,. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013; 73: 5315-5319.
10. Quintana E, Piskounova E, Shackleton M, et al., Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med 2012; 4: 159ra149.
11. Sharpless NE, Depinho RA,. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5: 741-754.
12. Singh M, Johnson L,. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 2006; 12: 5312-5328.
13. Rosenberg DW, Giardina C, Tanaka T,. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009; 30: 183-196.
14. Jonkers J, Derksen PW,. Modeling metastatic breast cancer in mice. J Mamm Gland Biol Neoplas 2007; 12: 191-203.
15. Heyer J, Kwong LN, Lowe SW, et al., Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010; 10: 470-480.
16. Kimlin LC, Casagrande G, Virador VM,. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2013; 52: 167-182.
17. Yauch RL, Settleman J,. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr Opin Genet Dev 2012; 22: 45-49.
18. Jia J, Zhu F, Ma X, et al., Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009; 8: 111-128.
19. Wong H, Choo EF, Alicke B, et al., Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 2012; 18: 3846-3855.
20. Wong H, Vernillet L, Peterson A, et al., Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res 2012; 18: 3090-3099.
21. Wong H, Alicke B, West KA, et al., Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 2011; 17: 4682-4692.
22. Gibbs JP,. Prediction of exposure-response relationships to support first-in-human study design. AAPS J 2010; 12: 750-758.
23. Alley MC, Hollingshead MG, Dykes DJ, et al., Human tumour xenograft models in NCI drug development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Teicher BA, Andrews PA, (eds). Humana: New York, NY, 2004; 125-152.
24. de Vries NA, Bruggeman SW, Hulsman D, et al., Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin Cancer Res 2010; 16: 3431-3441.
25. Singh M, Lima A, Molina R, et al., Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010; 28: 585-593.
26. Workman P, Aboagye EO, Balkwill F, et al., Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
27. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
28. Anderson K, Lutz C, van Delft FW, et al., Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
29. Al-Lazikani B, Banerji U, Workman P,. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30: 679-692.
30. Berns K, Bernards R,. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Update 2012; 15: 268-275.
31. Das Thakur M, Salangsang F, Landman AS, et al., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255.
32. Callahan MK, Rampal R, Harding JJ, et al., Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012; 367: 2316-2321.
33. Ribas A, Hodi FS, Callahan M, et al., Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366.
34. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
35. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
36. Francia G, Kerbel RS,. Raising the bar for cancer therapy models. Nat Biotechnol 2010; 28: 561-562.
37. Olive KP, Jacobetz MA, Davidson CJ, et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
38. Chen Z, Cheng K, Walton Z, et al., A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613-617.
39. Bertotti A, Migliardi G, Galimi F, et al., A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.
40. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al., Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013; 93: 252-259.
41. Politi K, Zakowski MF, Fan PD, et al., Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
42. Regales L, Gong Y, Shen R, et al., Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119: 3000-3010.
43. Janjigian YY, Smit EF, Horn L, et al., Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. In 37th ESMO Congress 2012, Vienna, Austria.
44. Pietras K, Ostman A,. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324-1331.
45. Tlsty TD, Coussens LM,. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-150.
46. Crawford Y, Kasman I, Yu L, et al., PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
47. Gilbert LA, Hemann MT,. DNA damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-366.
48. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
49. de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, et al., Cancer and immune response: old and new evidence for future challenges. Oncologist 2008; 13: 1246-1254.
50. Melero I, Hervas-Stubbs S, Glennie M, et al., Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
51. Kwon ED, Hurwitz AA, Foster BA, et al., Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94: 8099-8103.
52. Leach DR, Krummel MF, Allison JP,. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
53. van Elsas A, Hurwitz AA, Allison JP,. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366.
54. Sharma P, Wagner K, Wolchok JD, et al., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-812.
55. Wolchok JD, Kluger H, Callahan MK, et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
56. Vanneman M, Dranoff G,. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-251.
57. Gilbert LA, Hemann MT,. Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011; 71: 5062-5066.
58. Schilsky RL,. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med 2011; 3: 75cm79.
59. Workman P, Al-Lazikani B, Clarke PA,. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 2013; 13: 486-496.
60. Yap TA, Sandhu SK, Workman P, et al., Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10: 514-523.
61. Premsrirut PK, Dow LE, Kim SY, et al., A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011; 145: 145-158.
62. Pritchard JR, Bruno PM, Gilbert LA, et al., Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 2013; 110: E170-179.
63. Lesterhuis WJ, Haanen JB, Punt CJ,. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011; 10: 591-600.
64. Scher HI, Nasso SF, Rubin EH, et al., Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res 2011; 17: 6634-6640.
65. Sharma MR, Stadler WM, Ratain MJ,. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011; 103: 1093-1100.
66. Kummar S, Kinders R, Rubinstein L, et al., Compressing drug development timelines in oncology using phase.'0' trials. Nat Rev Cancer 2007; 7: 131-139.